Daily non-political popular news in brief.

Another 'smart' cancer drug can have toxic effects on the heart

Another FDA-approved targeted cancer drug, sunitinib, may be associated with cardiac toxicity, report researchers at Children's Hospital Boston, Dana-Farber Cancer Institute (Boston), and Thomas Jefferson University (Philadelphia). Sunitinib is one of several new "smart" cancer drugs called tyrosine kinase inhibitors that targets specific signaling molecules inside cancer cells that aid cancer spread, and was originally thought to be relatively free of cardiac side effects.

Read more »

Keywords: smart, cancer, drug, toxic, effects, heart, effect

« Previous | Next »

Similar news on "Another 'smart' cancer drug can have toxic effects on the heart":

1. Carbon monoxide counteracts one side-effect of an anti-cancer drug
   11-21-2007 · EurekAlert!
   Doxorubicin (DOX) is a red-colored anti-cancer drug that carries serious side effects for the heart. These cardio-toxic effects are due to inhibition by DOX of mitochondrial biogenesis, a term used to describe cellular energy generation. In a new study, it is now shown that mitochondrial biogenesis can be recovered in DOX-treated rodents by either inhalation of carbon monoxide or overexpression of the protein HO-1.
   Similar news · Read more »
   
2. Modifying an anti-cancer drug makes it more specific
   12-03-2007 · EurekAlert!
   Imatinib is used to treat chronic myeloid leukemia and gastrointestinal stromal tumors because they are caused by related proteins. However, this lack of specificity means imatinib also affects normal bodily functions and it has been reported to have a toxic effect on the heart in some patients. Now, researchers have modified imatinib so it inhibits the protein behind GISTs but neither inhibits the protein behind CML nor has toxic effects on the mouse heart.
   Similar news · Read more »
   
3. Study: Re-engineered Gleevec reduces heart risks
   12-03-2007 · EurekAlert!
   Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib -- best known by its brand name Gleevec -- to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect. The re-design strategy employed in the study is broadly applicable to reducing side effects in other drugs.
   Similar news · Read more »
   
4. Sunshine pill for prostate cancer in 2009
   01-16-2007 · EurekAlert!
   A drug based on vitamin D and is given to patients in the advanced stages of prostate cancer along with chemotherapy drugs could be availiable by 2009. Vitamin D from sunlight improves the prognosis of certain cancers, but taking natural levels of the vitamin has no effect. Novacea, the company that makes Asentar, produced a novel formulation that reproduces the healing effect without the dangerous side-effects of a vitamin D overdose.
   Similar news · Read more »
   
5. Chemical in red wine, fruits and vegetables stops cancer, heart disease, depending on the dose
   10-30-2007 · EurekAlert!
   The next cancer drug might come from the grocery store, according to research published in the November 2007 issue of the FASEB Journal. In the study, scientists describe how high and low doses of polyphenols have different effects. Most notably, they found that very high doses of polyphenols shut down and prevent tumors by stopping the formation of new blood vessels needed for growth. Polyphenols are found in red wine, fruits, vegetables and green tea.
   Similar news · Read more »
   
6. Study suggests newer breast cancer drug may protect heart
   06-08-2007 · EurekAlert!
   By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.
   Similar news · Read more »
   
7. Drug that interrupts a key stage of cell division shows promise for advanced solid tumors
   11-08-2006 · EurekAlert!
   One of the first studies to investigate the effects of a new anti-cancer drug in patients with advanced or metastatic solid tumours has shown that it is capable of halting progression of the disease, and the study has provided the first proof of the drug's mechanism of action, the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague was told on Wednesday.
   Similar news · Read more »
   
8. Common cancer treatments toxic to healthy brain cells
   11-29-2006 · EurekAlert!
   Common drugs used to treat cancer may be more harmful to healthy brain cells than the cancer cells that they are intended to destroy, according to a new study. The results, which also indicate that chemotherapy may cause long-term brain damage, represent the closest that scientists have come to pinpointing the underlying physiological cause of "chemo brain," a common side effect of cancer treatment that scientists are only now beginning to comprehend.
   Similar news · Read more »
   
9. It's never too late to get it back! Aging interrupted
   04-01-2007 · EurekAlert!
   Scientists have discovered that reducing calorie intake later in life can still induce many of the health and longevity benefits of life-long calorie reduction. Importantly, this also includes anti-cancer effects. They are using this knowledge to establish a novel screening technique to find drugs which mimic this longevity effect.
   Similar news · Read more »
   
10. Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
    01-21-2008 · EurekAlert!
    Findings by UT Southwestern Medical Center researchers encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.
    Similar news · Read more »